BCMA-targeted therapies for multiple myeloma: latest updates from 2024 ASH annual meeting

IF 29.5 1区医学 Q1 HEMATOLOGY

Journal of Hematology & Oncology Pub Date : 2025-03-01 DOI:10.1186/s13045-025-01675-5

Huijian Zheng, Huajian Xian, Wenjie Zhang, Chaoqun Lu, Renyao Pan, Han Liu, Zhenshu Xu

引用次数: 0

Abstract

B-cell maturation antigen (BCMA) is currently the most extensively explored target for multiple myeloma (MM). BCMA-targeted therapies such as antibody-drug conjugate (ADC), bispecific antibodies (BsAbs), chimeric antigen receptor T(CAR-T) cell have shown promising therapeutic prospects in MM. We have summarized the latest reports on the three types of drugs for MM at the 2024 ASH Annual Meeting.

查看原文本刊更多论文

多发性骨髓瘤的BCMA靶向疗法：2024年ASH年会的最新进展

B细胞成熟抗原（BCMA）是目前多发性骨髓瘤（MM）研究最广泛的靶点。以BCMA为靶点的疗法，如抗体-药物共轭物（ADC）、双特异性抗体（BsAbs）、嵌合抗原受体T（CAR-T）细胞等，在多发性骨髓瘤中已显示出良好的治疗前景。我们在2024年ASH年会上总结了这三种治疗MM药物的最新报道。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Hematology & Oncology 医学-血液学

CiteScore

48.10

自引率

2.10%

发文量

169

审稿时长

6-12 weeks

期刊介绍： The Journal of Hematology & Oncology, an open-access journal, publishes high-quality research covering all aspects of hematology and oncology, including reviews and research highlights on "hot topics" by leading experts. Given the close relationship and rapid evolution of hematology and oncology, the journal aims to meet the demand for a dedicated platform for publishing discoveries from both fields. It serves as an international platform for sharing laboratory and clinical findings among laboratory scientists, physician scientists, hematologists, and oncologists in an open-access format. With a rapid turnaround time from submission to publication, the journal facilitates real-time sharing of knowledge and new successes.